An observational study in California finds doxycycline post-exposure prophylaxis remains very effective against chlamydia and syphilis, but is not effective against gonorrhea.
Moderna has begun dosing participants in a phase 3 trial of its H5 pandemic flu vaccine candidate, mRNA-108.
The prevalence of XDR Shigella isolates in US surveillance data rose from 0% during 2011-2015 to 8.5% in 2023.
Syphilis cases in the Seattle area fell by 52% overall after the intervention was implemented, but no effect was seen on congenital syphilis.
The CDC and FDA continue to investigate the E coli outbreak, which has sickened 9 people in 3 states.
Complementary efforts, such as those that facilitate clinician adherence and ensure patient access to and treatment completion, would likely be needed for sustained impact.
Among gay and bisexual men with a history of gonorrhea infection who received either the 4CMenB vaccine or placebo, gonorrhea incidence was essentially the same—roughly 48% in both arms.
State health officials have identified 13 confirmed and 27 suspected cases of Trichophyton mentagrophytes type VII, a fungal skin infection that causes severe ringworm.
The increase follows a previously documented 222% surge from 2016 to 2022.
The European health agency says decisions on doxycycline post-exposure prophylaxis use should be made at the individual level, following clinical judgement and national guidelines.
